Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000658070 | SCV000705745 | uncertain significance | not provided | 2017-01-17 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000658070 | SCV000779841 | uncertain significance | not provided | 2018-05-21 | criteria provided, single submitter | clinical testing | The T174M variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The T174M variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016). The T174M variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. In-silico analyses, including protein predictors and evolutionary conservation, support that this variant does not alter protein structure/function. In summary, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benign variant. |
Labcorp Genetics |
RCV000697734 | SCV000826361 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2023-11-07 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002491201 | SCV002775277 | uncertain significance | Alagille syndrome due to a JAG1 point mutation; Tetralogy of Fallot; Deafness, congenital heart defects, and posterior embryotoxon; Charcot-Marie-Tooth disease, axonal, Type 2HH | 2022-02-05 | criteria provided, single submitter | clinical testing |